I
IrisVision
Breakthrough wearable headset that allows the vision impaired and macular degeneration, to see clearly and live fully
About IrisVision
IrisVision is a pioneering company in the field of low vision assistive technology, leveraging advanced virtual reality (VR) to help visually impaired individuals manage their vision health. The company operates in the healthcare market, specifically targeting patients with low vision, including those who have lost most but not all of their sight. IrisVision's core product is a set of low vision glasses that are medically validated and approved by the National Institutes of Health (NIH). These glasses offer a life-changing solution that can be experienced from the safety of one's home. The business model includes direct sales to consumers and partnerships with distributors, providing a 30-day risk-free trial to ensure customer satisfaction. Revenue is generated through the sale of these advanced low vision aids and associated services, such as remote screening, training, and support. IrisVision's mission is to make vision health accessible to everyone, focusing on even the most challenged and at-risk patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Pleasanton, United States
- Employees
- 48
- Open positions
- None listed
- Dealroom signal
- 27.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Core AI, Immersive Technologies, Spinout
- Technology
- Artificial Intelligence, Hardware, Deep Tech, Virtual Reality, Computer Vision, Connected Device, IoT InternetOfThings
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning IrisVision.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2022 | $12M | $47M | Undisclosed | ↗ |
| EARLY VCEquity / VC | Sep 2021 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for IrisVision is 14K monthly website visits, down 6.7% over the last three months. IrisVision's team grew 6.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
HealthTech Capital
Joyance Partners
Other known investors5 additional known investors
Johns Hopkins University
University of California, Berkeley
Band of Angels
Outcomes Collective
Social Starts
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IrisVision on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IrisVision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.